Chimeric TherapeuticsCHMMF -96.67%13 Net Debt Paydown Yield % is 0% as of Jul. 07, 2026. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,159 Biotechnology companies, Chimeric Therapeutics ranks worse than 86281.19% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Chimeric Therapeutics's Net Debt Paydown Yield % was 0%.
Chimeric Therapeutics (OTCPK:CHMMF) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Chimeric Therapeutics Net Debt Paydown Yield % Related Terms
Chimeric Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics Net Debt Paydown Yield % Chart
CHMMF vs VRTX, REGN, ALNY: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Chimeric Therapeutics (CHMMF) has a Net Debt Paydown Yield % of 0% as of Jul. 07, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #999999 out of 1159 companies in the Biotechnology industry.
Is Chimeric Therapeutics' Net Debt Paydown Yield % too high?
Chimeric Therapeutics' current Net Debt Paydown Yield % is 0%. Based on the distribution chart, Chimeric Therapeutics ranks #999999 out of 1159 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Net Debt Paydown Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #999999 out of 1159 companies for Net Debt Paydown Yield %. This places Chimeric Therapeutics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Net Debt Paydown Yield % of 0%. The current Net Debt Paydown Yield % is 0%. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Net Debt Paydown Yield % is 0% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
